Weinstock, M. A., Lew, R. A., Shaw, F. M., & Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group, . (2018). Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply. JAMA Dermatol, 154(7), 851–852. https://doi.org/10.1001/jamadermatol.2018.1230

Weinstock, Martin A., Robert A. Lew, Fiona M. Shaw, and Fiona M. Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. “Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply.” JAMA Dermatol 154, no. 7 (July 1, 2018): 851–52. https://doi.org/10.1001/jamadermatol.2018.1230.

Weinstock MA, Lew RA, Shaw FM, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply. JAMA Dermatol. 2018 Jul 1;154(7):851–2.

Weinstock, Martin A., et al. “Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply.” JAMA Dermatol, vol. 154, no. 7, July 2018, pp. 851–52. Pubmed, doi:10.1001/jamadermatol.2018.1230.

Weinstock MA, Lew RA, Shaw FM, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply. JAMA Dermatol. 2018 Jul 1;154(7):851–852.